ArticleArtificial organs2026
Post-Market Analysis of the Xenios Console With the Xlung Tubing Kit 230 for Extracorporeal Membrane Oxygenation After Cardiac Surgery.
Article in Artificial organs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe use of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) has led to an increasing number of devices available on the market. Most studies pay less attention to which devices have been used; therefore, the information on performance for each device is limited. The current study is a comprehensive post-market analysis of all the major functions and adverse events rates of the Xenios console and XLung kit 230 preconfigured ECMO tubing set in post-cardiotomy applications.
methodsThis retrospective, single-center analysis, conducted between 2017 and 2021, included 47 adult patients who received V-A ECMO support using the Xenios system following cardiac surgery at our institution.
resultsThe Xenios device was found to effectively improve and maintain microcirculation, organ perfusion, gas exchanges, organ function support, and stabilization of the cardiocirculatory system, while maintaining pump performance and stable body core temperature. Device-related adverse events occurred in 28% of patients but resolved in 81% of cases without leaving clinical sequelae. Fewer hemolysis events than reported in the literature were recorded. Every patient experienced at least two patient-related adverse events, but 43% had no relation to the device and 45% resolved without permanent damage.
conclusionsThe performance of the evaluated device was demonstrated in all key clinical areas, with an adequate safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.